Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: peregrine pharmaceuticals + bavituximab phase + bavituximab  Related to the article below (Last Update: 5/12/2008)

Peregrine Pharmaceuticals Completes Patient Enrollment in First ...
CNNMoney.com (press release) - Apr 29, 2008
Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. ...PPHM
Preclinical Study Presented at AACR Annual Meeting Shows ...
Earthtimes, UK - Apr 15, 2008
Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. ...PPHM
Peregrine's antibody targets tumors
Therapeutics Daily (subscription) (press release), PA - Apr 22, 2008
USA-based Peregrine Pharmaceuticals has reported favorable results for its Phase II trials of its cancer treatment bavituximab (Marketletters passim). ...PPHM
Affitech Announces Achievement of Significant Milestone in ...
Business Wire (press release), CA - May 6, 2008
Peregrine currently has an anti-PS antibody, bavituximab, that is in phase II clinical trials for the treatment of breast and lung cancers and in a phase I ...PPHM
Other News To Note
TMCnet - May 6, 2008
Peregrine currently has an anti-PS antibody, bavituximab, which is in Phase II trials for the treatment of breast and lung cancers and in a Phase I study ...
AACR Roundup
TMCnet - Apr 15, 2008
A separate poster described the mechanism of bavituximab and PGN635 (a fully human version of the bavituximab antibody), both of which affect the tumor ...
Peregrine Pharma Completes Patient Enrollment In First Stage Of ...
RTT News, NY - Apr 29, 2008
4/29/2008 10:59:42 AM Peregrine Pharmaceuticals Inc. (PPHM) said that it has completed enrollment in the first stage of its Phase II trial of bavituximab in ...PPHM
Peregrine Researchers Present New Preclinical Data at AACR Annual ...
Biloxi Sun Herald,  USA - Apr 15, 2008
Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. ...
Access Pharmaceuticals Presents New Data on ProLindac(TM) at the ... PR Newswire (press release)
all 15 news articles »  PPHM - OTC:ACCP
Market Report -- In Play (WIRES)
MSN Money - Apr 29, 2008
On The Wires Peregrine Pharmaceuticals (PPHM) announces that it has completed enrollment in the first stage of its Phase II trial of bavituximab in ...PPHM

In order to show you the most relevant results, we have omitted some entries very similar to the 9 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

Bavituximab* has shown potential in the treatment of patients with chronic hepatitis C virus …
RL Pharmanewsfeed - Inpharma Weekly, 2007 - inpharma.adisonline.com
... 1. Peregrine Pharmaceuticals.Peregrine Pharmaceuticals Reports Positive Phase Ib
Results for its Targeted Immunotherapy Bavituximab in Chronic Hepatitis C ...

Recent R&D Highlights
P Pharmaceuticals - Pharmaceutical & Diagnostic Innovation, 2006 - ingentaconnect.com
... currently being studied in phase I clinical trials in the US ... (PS), the target for
Peregrine?s Tarvacin? (bavituximab) ... 1. Peregrine Pharmaceuticals. ...

Antivirals?an increasingly healthy investment -
B McCarthy - Nature Biotechnology, 2007 - nature.com
... Even so, Peregrine Pharmaceuticals (Tustin, CA, USA) is developing bavituximab,
which targets ... The company announced phase 1b results at AASLD, demonstrating ...
-

Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds … -
M Jennewein, MA Lewis, D Zhao, E Tsyganov, N … - Clinical Cancer Research, 2008 - AACR
... Bavituximab is currently in phase I clinical trials in ... Bavituximab was provided by
Peregrine Pharmaceuticals, Inc ... Bavituximab is a chimeric antibody composed of ...
-

Carbon nanotubes: new weapons against cancer
A Options, TOC Latest - Expert Review of Anticancer Therapy, 2007 - ingentaconnect.com
... Peregrine Pharmaceuticals, Inc. ... new clinical trials using a combination of bavituximab
and radiotherapy ... by the National Cancer Institute and Phase I clinical ...

Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections. -
JM Reichert - BioDrugs, 2007 - biodrugs.adisonline.com
... The third mAb, bavituximab (Peregrine Pharmaceutical, Tustin, CA, USA), is in phase
I development as a treatment for HCV infection, although this mAb has the ...

[PDF] The growth and potential of human antiviral monoclonal antibody therapeutics -
WA Marasco, J Sui - NATURE BIOTECHNOLOGY, 2007 - nature.com
... 60 Phase 1/2 trial showed it is safe, well tolerated and similar ... Intravenous HCV
immunoglobulin Civacir a Nabi Pharmaceuticals (Boca Raton, FL, USA) Prevention ...
-

[PDF] Future therapies for hepatitis C -
JM Pawlotsky, RG Gish - Antivir Ther, 2006 - hepcchallenge.org
... Phase I trials Anadys Pharmaceuticals ANA971 Nucleoside analogue, TLR7 agonist ...
Peregrine Pharmaceuticals Bavituximab Anti-phospholipid ...
-

The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases -
JN Rybak, C Roesli, M Kaspar, A Villa, D Neri - Cancer Research, 2007 - AACR
... endometrium in the proliferative phase and some ... version of 3G4 (tarvacin/bavituximab)
is currently ... for oncological applications (Peregrine Pharmaceuticals, Inc ...

7 Development of Antiangiogenic Monoclonal Antibodies for Cancer Therapy
Z Zhu, DJ Hicklin - Antiangiogenic Cancer Therapy, 2007 - books.google.com
... important drug class in pharmaceutical development and ... Phase I Phase I Phase I
Preclinical ... Incorporated ImClone Systems Incorporated Peregrine of endothelial ...
-

Source: Google Scholar

Peregrine Pharmaceuticals Submits Clinical Protocol To Initiate Bavituximab Phase II Trial In Lung Cancer Patients
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has submitted a clinical protocol with the Drug Controller General of India (DCGI) for a Phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC). The multi-center trial is expected to begin enrolling patients once the protocol regulatory review is completed.
The trial has a two-stage design. Up to 21 NSCLC patients will be enrolled initially and the study will be expanded up to a total of 49 patients if positive results are observed in the first cohort. The primary objective of the Phase II study is to assess overall response rate to the combination of bavituximab and chemotherapy. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients will receive up to six cycles of chemotherapy with weekly administration of bavituximab until their cancer progresses.

"Submitting this Phase II clinical protocol represents a significant milestone for the bavituximab cancer program," said Steven W. King, president and CEO of Peregrine. "This trial builds on data generated from a recently completed Phase Ib clinical study in which bavituximab was administered in combination with chemotherapy, including carboplatin and paclitaxel. Results from that study indicated that the combination of bavituximab with paclitaxel and carboplatin was particularly promising, with encouraging signs of anti-tumor activity and a safety profile that appeared to be consistent with chemotherapy alone. We look forward to assessing its potential in this larger trial in patients with non-small cell lung cancer, a condition that currently lacks effective treatment options."

Tumor response will be evaluated every other month using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine (PS), normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib trial to assess its safety in combination with common chemotherapy agents in advanced cancer patients with metastatic disease, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Bavituximab is currently in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.
About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from this Phase II trial will not correlate with the results from the Phase Ib trial, the risk that bavituximab will not be as well tolerated by patients with non small cell lung cancer, and the risk that enrollment rates in the trial will be slower than anticipated. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by all a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Peregrine Pharmaceuticals, Inc.
http://www.peregrineinc.com
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.